On June 3, the signing ceremony of strategic cooperation between Faber Xintian and HTA was held in Beijing. Du Jin, Chief scientist of CNNC and President of China Tongfu Research Institute, Li Guoxiang, Deputy Party Secretary and deputy general manager of HTA, Sui Yanying and Zhang Xuefeng, Chief Administrative Officer Wang Chun, Senior Vice President and Chief Technology Officer Nian Jinxing, Chief Operating Officer Wang Tong and Vice President Dai Bo attended the signing ceremony. Wang Chun and Sui Yanying signed a strategic cooperation agreement on the development and commercialization of the targeted radioactive new drug PMD12 on behalf of both parties.
PMD12 is a specific tumor diagnostic imaging agent, and the preliminary IIT data show that its diagnostic efficacy is clear, and it has a variety of tumor diagnosis potential. The two sides work together to promote the clinical transformation and commercialization of PMD12 layout construction, in line with the "Medium and long-term development Plan for Medical isotopes (2021-2035)" and "county general hospital equipment configuration standards" proposed by the "one county, one department" and other development planning requirements, in order to achieve the modernization of China's health field governance capacity.
Wang Chun said that Faber Xintian is an innovative drug research and development company focusing on molecular imaging diagnosis and radiopharmaceutical therapy, insisting on innovation-driven development, establishing a radiopharmaceutical transformation platform, maintaining stability and improving quality, and building strength. The company attaches great importance to the strategic cooperation with HTA, with its own flexibility and innovation ability, combined with the resource advantages and stability of state-owned enterprises, can accelerate the transformation and promotion of products, and add joint efforts to meet the growing health needs of the people.
Sui Yanying said that HTA and Faber Xintian have always maintained a good cooperative relationship and have high expectations for this strategic cooperation. Based on the innovative cooperation mode between state-owned enterprises and new enterprises engaged in the radiopharma industry, the two sides jointly promote the deep integration of the innovation chain and the industrial chain, draw on each other's strengths to lead the leapfrog development of the nuclear technology application field, promote the development of the national nuclear medical and health industry, and promote the early realization of the healthy China construction strategy.
Li Guoxiang said that HTA has deep accumulation and excellent strength in radiopharmaceutical research and development, production, marketing and distribution. This signing is an important cooperation between the two sides based on the common vision and development goals, and is the opening of a new chapter of in-depth cooperation between the two sides. We believe that through the combination of the two sides, we will bring more effective products and services to the pharmaceutical market and patients.
Du affirmed that pharmaceutical studies and clinical data of PMD12 show good diagnostic effects and its potential in broad-spectrum diagnosis of tumors. Du Jin stressed that the two sides should take this strategic cooperation agreement as an opportunity to rationally plan follow-up cooperation, complement each other's advantages and achieve win-win cooperation.
